Zentalis Pharmaceuticals, Inc.
ZNTLAs of the close on Sep 25, 2026
Price
$2.70
Market cap
$194M
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.96
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Zentalis Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Zentalis Pharmaceuticals, Inc. — 10-K filed Mar 26, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Creative Planning | 2026-03-31 | 285,000 | $667K | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 591,217 | $1.38M | SEC filing |
| Seven Fleet Capital Management LP | 2026-03-31 | 110,000 | $257K | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 113,126 | $242K | SEC filing |
| Pfizer Inc | 2026-03-31 | 953,834 | $2M | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 77,300 | $181K | SEC filing |
| Brevan Howard Capital Management LP | 2026-03-31 | 47,063 | $110K | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 98,554 | $231K | SEC filing |
| Woodline Partners LP | 2026-03-31 | 266,032 | $623K | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 471,438 | $1.1M | SEC filing |
| Opaleye Management Inc. | 2026-03-31 | 1,412,656 | $3.31M | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 637,116 | $1.49M | SEC filing |
| PRUDENTIAL FINANCIAL INC | 2026-03-31 | 20,850 | $48.8K | SEC filing |
| Quadrature Capital Ltd | 2026-03-31 | 33,332 | $78K | SEC filing |
| Hudson Bay Capital Management LP | 2026-03-31 | 117,127 | $274K | SEC filing |
| Squadron Capital Management LLC | 2026-03-31 | 3,631,000 | $8.5M | SEC filing |
| Invesco Ltd. | 2026-03-31 | 125,767 | $294K | SEC filing |
| PRELUDE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 20,400 | $47.7K | SEC filing |
| Silicon Valley Capital Partners | 2026-03-31 | 84 | $197 | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2026-03-31 | 620,407 | Not shown | SEC filing |
- Each value is checked against Zentalis Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Zentalis Pharmaceuticals, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- STATE STREET CORP: 271,790 shares reported 2025-12-31; 249,690 shares reported 2026-03-31.
- Wilmington Savings Fund Society, FSB: 1,000 shares reported 2025-12-31; 1,000 shares reported 2026-03-31.
- SEI INVESTMENTS CO: 167,100 shares reported 2025-12-31; 191,551 shares reported 2026-03-31.
- COMMONWEALTH EQUITY SERVICES, LLC: 61,412 shares reported 2025-12-31; 61,412 shares reported 2026-03-31.
- BlackRock, Inc.: 1,249,968 shares reported 2025-12-31; 1,269,837 shares reported 2026-03-31.
- CITADEL ADVISORS LLC: 1,964,255 shares reported 2025-12-31; 1,732,083 shares reported 2026-03-31.
- 5AM Venture Management, LLC: 3,947,913 shares reported 2025-12-31; 3,947,913 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 589,105 shares reported 2025-12-31; 621,036 shares reported 2026-03-31.
- JANE STREET GROUP, LLC: 473,175 shares reported 2025-12-31; 490,339 shares reported 2026-03-31.
- FEDERATED HERMES, INC.: 34,574 shares reported 2025-12-31; 65,520 shares reported 2026-03-31.
- ACADIAN ASSET MANAGEMENT LLC: 2,849,294 shares reported 2025-12-31; 2,848,252 shares reported 2026-03-31.
- Almitas Capital LLC: 610,073 shares reported 2025-12-31; 610,073 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
82 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Zentalis Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-06 · Vultaggio Vincent: Larger than 136 of the 137 other insider sales of Common Stock on file. SEC filing
- 2025-02-03 · Lackner Mark: Larger than 133 of the 137 other insider sales of Common Stock on file. SEC filing
- 2025-02-03 · Paul Andrea: Larger than 132 of the 137 other insider sales of Common Stock on file. SEC filing
- 2024-02-02 · Gallagher Cam: Larger than 127 of the 137 other insider sales of Common Stock on file. SEC filing
- 2023-05-31 · Gallagher Cam: Larger than 134 of the 137 other insider sales of Common Stock on file. SEC filing
- 2023-05-26 · Bunker Kevin D.: Larger than all 137 other insider sales of Common Stock on file. SEC filing
- 2022-11-15 · Gallagher Cam: Larger than 128 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-11-08 · Gallagher Cam: Larger than 130 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-11-07 · Gallagher Cam: Larger than 129 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-10-17 · Gallagher Cam: Larger than 131 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-10-06 · Gallagher Cam: Larger than 125 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-07-05 · Bunker Kevin D.: Larger than 135 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-04-04 · SUN ANTHONY Y: Larger than 126 of the 137 other insider sales of Common Stock on file. SEC filing
- 2022-03-02 · SUN ANTHONY Y: Larger than 124 of the 137 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-01-31–2025-02-06: 4 event(s) across 4 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
- 2023-11-10–2023-11-13: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-10 | Vultaggio Vincent · PAO and PFO | Common Stock | S — Open market or private sale | −6,894 | 2.42 | SEC filing |
| 2026-02-09 | EASTLAND JULIA MARIE · CEO & President | Common Stock | S — Open market or private sale | −889 | 2.39 | SEC filing |
| 2026-02-09 | Vultaggio Vincent · PAO and PFO | Common Stock | S — Open market or private sale | −3,379 | 2.39 | SEC filing |
| 2026-02-09 | Bruns Ingmar · Chief Medical Officer | Common Stock | S — Open market or private sale | −335 | 2.39 | SEC filing |
| 2026-02-06 | Bruns Ingmar · Chief Medical Officer | Common Stock | S — Open market or private sale | −2,962 | 2.43 | SEC filing |
| 2026-02-06 | Vultaggio Vincent · PAO and PFO | Common Stock | S — Open market or private sale | −29,951 | 2.43 | SEC filing |
| 2026-02-06 | EASTLAND JULIA MARIE · CEO & President | Common Stock | S — Open market or private sale | −7,866 | 2.43 | SEC filing |
| 2026-02-03 | Vultaggio Vincent · PAO and PFO | Common Stock | S — Open market or private sale | −556 | 2.52 | SEC filing |
Showing 8 of 19 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Walker Luke Nathaniel · Director | Common Stock | A — Grant, award, or other acquisition | +57,100 | SEC filing |
| 2026-06-16 | Johnson David Michael · Director | Common Stock | A — Grant, award, or other acquisition | +57,100 | SEC filing |
| 2026-06-16 | Myers Scott Dunseth · Director | Common Stock | A — Grant, award, or other acquisition | +57,100 | SEC filing |
| 2026-06-16 | Kariuki Enoch · Director | Common Stock | A — Grant, award, or other acquisition | +57,100 | SEC filing |
| 2026-06-16 | Skvarka Jan · Director | Common Stock | A — Grant, award, or other acquisition | +57,100 | SEC filing |
| 2026-05-26 | Campbell Shannon · Director | Common Stock | A — Grant, award, or other acquisition | +114,200 | SEC filing |
| 2026-01-08 | Bruns Ingmar · Chief Medical Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +365,000 | SEC filing |
| 2026-01-08 | Bucher James B · Chief Legal Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +100,000 | SEC filing |
Showing 8 of 19 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.